Tags

Type your tag names separated by a space and hit enter

Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study.
Dermatol Surg. 2004 Feb; 30(2 Pt 1):130-5.DS

Abstract

BACKGROUND

Vitiligo is an acquired skin disorder that is characterized by well-defined, often symmetric white patches. Although current therapeutic modalities are directed toward increasing melanocyte melanin production, few treatment modalities address the immunologic nature of the disease.

OBJECTIVE

To determine whether excimer laser, a known therapeutic modality, in combination with tacrolimus, a topical immunomodulator, accelerate response time and/or improve the degree of response in patients with this disorder.

METHODS

Eight subjects diagnosed with vitiligo were recruited to participate in this institutional review board-approved double-blind, placebo-controlled study. Twenty-four symmetric vitiliginous patches (elbows, knees) from eight subjects received excimer laser treatment three times per week for 24 treatments or 10 weeks. Additionally, topical tacrolimus 0.1% ointment (Protopic) and placebo (Aquaphor) were applied to randomized patches (left or right) twice daily throughout the length of the trial. Vitiliginous patches were monitored with photographs at baseline, every 2 weeks, and 6 months after treatment. Biopsies were performed on subjects with significant results.

RESULTS

Twenty vitiliginous patches from six subjects qualified for evaluation. Fifty percent of patches treated with combination excimer laser and tacrolimus achieved a successful response (75% repigmentation) compared with 20% for the placebo group. Subjects who responded successfully repigmented faster (19%) with combination therapy compared with excimer laser alone. Additionally, three subjects experienced transient hyperpigmentation in lesions treated with combination therapy.

CONCLUSION

Combining topical immunomodulators with known phototherapeutic modalities may represent a key advancement in the treatment of disease.

Authors+Show Affiliations

Department of Dermatology Mount Sinai School of Medicine, New York, New York, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

14756638

Citation

Kawalek, Adam Z., et al. "Combined Excimer Laser and Topical Tacrolimus for the Treatment of Vitiligo: a Pilot Study." Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.], vol. 30, no. 2 Pt 1, 2004, pp. 130-5.
Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg. 2004;30(2 Pt 1):130-5.
Kawalek, A. Z., Spencer, J. M., & Phelps, R. G. (2004). Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.], 30(2 Pt 1), 130-5.
Kawalek AZ, Spencer JM, Phelps RG. Combined Excimer Laser and Topical Tacrolimus for the Treatment of Vitiligo: a Pilot Study. Dermatol Surg. 2004;30(2 Pt 1):130-5. PubMed PMID: 14756638.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. AU - Kawalek,Adam Z, AU - Spencer,James M, AU - Phelps,Robert G, PY - 2004/2/6/pubmed PY - 2004/4/7/medline PY - 2004/2/6/entrez SP - 130 EP - 5 JF - Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] JO - Dermatol Surg VL - 30 IS - 2 Pt 1 N2 - BACKGROUND: Vitiligo is an acquired skin disorder that is characterized by well-defined, often symmetric white patches. Although current therapeutic modalities are directed toward increasing melanocyte melanin production, few treatment modalities address the immunologic nature of the disease. OBJECTIVE: To determine whether excimer laser, a known therapeutic modality, in combination with tacrolimus, a topical immunomodulator, accelerate response time and/or improve the degree of response in patients with this disorder. METHODS: Eight subjects diagnosed with vitiligo were recruited to participate in this institutional review board-approved double-blind, placebo-controlled study. Twenty-four symmetric vitiliginous patches (elbows, knees) from eight subjects received excimer laser treatment three times per week for 24 treatments or 10 weeks. Additionally, topical tacrolimus 0.1% ointment (Protopic) and placebo (Aquaphor) were applied to randomized patches (left or right) twice daily throughout the length of the trial. Vitiliginous patches were monitored with photographs at baseline, every 2 weeks, and 6 months after treatment. Biopsies were performed on subjects with significant results. RESULTS: Twenty vitiliginous patches from six subjects qualified for evaluation. Fifty percent of patches treated with combination excimer laser and tacrolimus achieved a successful response (75% repigmentation) compared with 20% for the placebo group. Subjects who responded successfully repigmented faster (19%) with combination therapy compared with excimer laser alone. Additionally, three subjects experienced transient hyperpigmentation in lesions treated with combination therapy. CONCLUSION: Combining topical immunomodulators with known phototherapeutic modalities may represent a key advancement in the treatment of disease. SN - 1076-0512 UR - https://www.unboundmedicine.com/medline/citation/14756638/Combined_excimer_laser_and_topical_tacrolimus_for_the_treatment_of_vitiligo:_a_pilot_study_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1076-0512&date=2004&volume=30&issue=2 Pt 1&spage=130 DB - PRIME DP - Unbound Medicine ER -